Sight Sciences, Inc.

Listed Company

SGHTCIK 0001531177NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$77.36M

Net Income

$-38.40M

Total Assets

$115.30M

Equity

$63.94M

Shares Out

54.01M

Op. Cash Flow

$-29.69M

Business

Sight Sciences, Inc. develops and commercializes interventional ophthalmology technologies to procedurally treat glaucoma and dry eye disease. Its principal products and services include the OMNI surgical system and SION surgical instrument for microinvasive glaucoma surgery and the TearCare system for meibomian gland dysfunction and evaporative dry eye, supported by clinical trials, training, and market access initiatives. The company operates through two primary business segments—Surgical Glaucoma and Dry Eye—each supported by distinct sales, marketing, and training functions. It distributes products primarily in the United States with direct sales to ambulatory surgery centers, hospital outpatient departments, and eyecare practices, and maintains operations and distributor relationships in the United Kingdom, Germany and other European countries.

Summary from filing dated 2025-03-07

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	77	80	81	71	49
Cost of goods sold	11	12	12	12	9
Gross profit	67	68	69	59	40
Research and development	15	18	18	23	16
Selling, general and administrative	89	101	109	120	76
Total operating expenses	104	119	126	143	92
Loss from operations	−37	−51	−57	−84	−51
Investment income	4	6	7	—	—
Interest expense	−5	−5	−5	−4	−4
Loss on debt extinguishment	0	−2	0	—	—
Other expense, net	−148,000	−32,000	−44,000	2	−7
Loss before income taxes	−38	−51	−55	−86	−63
Provision for income taxes	10,000	236,000	110,000	47,000	188,000
Net loss and comprehensive loss	−38	−52	−56	−86	−63
Net loss per share attributable to common stockholders-basic	−0.74	−1.03	−1.14	−1.8	−2.36
Net loss per share attributable to common stockholders-diluted	−0.74	−1.03	−1.14	−1.8	−2.36
Weighted-average shares of common stock outstanding-basic	52	50	49	48	27
Weighted-average shares of common stock outstanding-diluted	52	50	49	48	27

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	92	120	138	185	261
Accounts receivable, net of allowance for credit losses of $234 and $689 at December 31, 2025 and 2024, respectively	10	11	14	15	9
Inventory, net	8	6	8	6	3
Prepaid expenses and other current assets	3	2	3	3	4
Total current assets	113	140	163	210	277
Property and equipment, net	2	2	2	2	1
Operating lease right-of-use assets	438,000	935,000	1	2	1
Other noncurrent assets	518,000	550,000	682,000	211,000	202,000
Total assets	115	143	167	213	280
Accounts payable	1	2	2	3	3
Accrued compensation	6	10	5	7	6
Accrued and other current liabilities	4	4	4	8	4
Total current liabilities	11	15	12	18	14
Long-term debt, net of current portion	40	39	32	33	33
Other noncurrent liabilities	31,000	492,000	2	2	2
Total liabilities	51	55	46	53	48
Commitments and contingencies (Note 6)	—	—	—	—	—
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024, respectively	0	0	0	0	0
Common stock, par value $0.001 per share; 200,000,000 shares authorized; 53,493,711 and 50,937,999 shares issued and outstanding as of December 31, 2025 and 2024, respectively	54,000	51,000	49,000	48,000	48,000
Additional paid-in-capital	449	434	415	399	385
Accumulated deficit	−385	−346	−295	−239	−153
Total stockholders' equity	64	88	120	160	232
Total liabilities and stockholders' equity	115	143	167	213	280

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−38	−52	−56	−86	−63
Depreciation and amortization	487,000	712,000	614,000	—	—
Accretion of debt discount and debt issuance costs	944,000	753,000	614,000	657,000	701,000
Stock-based compensation expense	13	17	15	13	5
Allowance for credit losses	129,000	−42,000	198,000	402,000	348,000
Provision (benefit) for excess and obsolete inventories	0	−106,000	418,000	614,000	436,000
Noncash operating lease cost	498,000	646,000	1	542,000	569,000
Loss on disposal of property and equipment	4,000	23,000	66,000	85,000	115,000
Noncash loss on debt extinguishment	0	1	0	—	—
Change in fair value of common stock warrants	11,000	60,000	0	0	7
Accounts receivable	912,000	4	661,000	−7	−4
Inventory	−1	2	−2	−3	−1
Prepaid expenses and other current assets	−686,000	299,000	812,000	751,000	−3
Other noncurrent assets	−150,000	−51,000	−470,000	−10,000	185,000
Accounts payable	−348,000	336,000	−883,000	−694,000	1
Accrued compensation	−4	5	−3	1	2
Accrued and other current liabilities	−1	−347,000	−5	3	342,000
Other noncurrent liabilities	0	−2	330,000	353,000	72,000
Net cash used in operating activities	−30	−22	−47	−76	−53
Purchases of property and equipment	−224,000	−385,000	−791,000	−970,000	−813,000
Net cash used in investing activities	−224,000	−385,000	−791,000	−970,000	−813,000
Net proceeds from Hercules Loan Agreement	0	40	0	—	—
Repayment of MidCap Loan Agreement	0	−35	0	—	—
Debt issuance costs	0	−238,000	0	—	0
Proceeds from exercise of common stock options	1	255,000	395,000	576,000	355,000
Taxes paid on net settlement of restricted stock units	−58,000	−23,000	−224,000	0	—
Proceeds from employee stock purchase plan purchases	758,000	819,000	933,000	672,000	0
Net cash provided by financing activities	2	5	1	1	253
Net change in cash and cash equivalents	−28	−18	−47	−76	199
Cash paid for interest	4	4	4	3	3
Acquisition of property and equipment included in accounts payable and accrued liabilities	114,000	169,000	60,000	103,000	162,000
Common stock warrants issued upon execution of Hercules Loan Agreement	0	687,000	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro